Literature DB >> 9537846

Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C.

C Zavaglia1, M Martinetti, E Silini, R Bottelli, C Daielli, M Asti, A Airoldi, L Salvaneschi, M U Mondelli, G Ideo.   

Abstract

BACKGROUND/AIMS: Recent studies have suggested that the course of chronic hepatitis C may be influenced by the immunogenetic background of the host. Specifically, HLA-DR11 (5) has been associated with less advanced hepatitis C virus (HCV)-related liver disease. The aim of the present study was to investigate whether HLA-DRB1*11 subtypes or HLA-DQA1 and DQB1 genes might be associated with protection from or susceptibility to chronic HCV infection, histological severity of HCV-induced liver disease and infecting HCV genotype.
METHODS: Ninety-nine unrelated outpatients with histologically documented chronic hepatitis C were studied and their allele frequencies were compared with those of 179 ethnically matched controls and with those of 41 HCV RNA-positive patients with persistently normal aminotransferase levels (HCV carriers). HLA-DQ types and HLA-DRB1*11 subtypes were determined by polymerase chain reaction gene amplification with sequence specific primers.
RESULTS: None of 10 DQA1 or 12 DQB1 alleles was significantly associated with susceptibility to or protection from chronic HCV infection or with histological staging or with HCV genotype. However, analysis of DQA1-DQB1 combinations showed that DQA1*0201-DQB1*0201 combination was significantly more frequent in patients compared to controls, both in cis (26.3% vs 16.2%, p = 0.04, odds ratio = 1.8, 95% confidence interval, 0.96-3.5) and in trans (12.1% vs. 1.1%, p = 0.0001, OR = 12.2, 95% CI, 2.6-113.7). HCV carriers did not differ from controls or from patients in the frequency of DQA1-DQB1 combinations. The extended haplotype DRB1*1104, DQA1*0501, DQB1*0301 was seen significantly less frequently in patients than in controls (8% vs 22.3%, p = 0.0025, OR = 0.31, 95% CI, 0.12-0.7) or HCV-RNA carriers (8% vs 26.8%, p = 0.003, OR = 0.24, 95% CI, 0.08-0.73).
CONCLUSIONS: Immunogenetic factors may play a role in determining both protection from and susceptibility to chronic hepatitis C, the trans-dimer DQA1*0201-DQB1*0201 predisposing to and the DRB1*1104, DQA1*0501, DQB1*0301 haplotype protecting from chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537846     DOI: 10.1016/s0168-8278(98)80195-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

Review 1.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis.

Authors:  Xin Hong; Rong-Bin Yu; Nan-Xiong Sun; Bin Wang; Yao-Chu Xu; Guan-Ling Wu
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.

Authors:  Ankur Goyal; P V Suneetha; G T Kumar; Deepak K Shukla; Naveen Arora; Shiv K Sarin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection.

Authors:  Ayla Yenigün; Belma Durupinar
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 5.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 6.  Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome.

Authors:  Viviana Romero; Jose Azocar; Joaquin Zúñiga; Olga P Clavijo; Daniel Terreros; Xiangjun Gu; Zaheed Husain; Raymond T Chung; Christopher Amos; Edmond J Yunis
Journal:  Mol Immunol       Date:  2008-03-04       Impact factor: 4.407

7.  Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans.

Authors:  Rebecca A Harris; Kazushi Sugimoto; David E Kaplan; Fusao Ikeda; Malek Kamoun; Kyong-Mi Chang
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 8.  A comparative review of HLA associations with hepatitis B and C viral infections across global populations.

Authors:  Rashmi Singh; Rashmi Kaul; Anil Kaul; Khalid Khan
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

Review 9.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells.

Authors:  A Takaki; M Tatsukawa; Y Iwasaki; K Koike; Y Noguchi; H Shiraha; K Sakaguchi; E Nakayama; K Yamamoto
Journal:  J Viral Hepat       Date:  2009-10-04       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.